Thanks for posting. The study posted was a Vero cell study of several potential antivirals.
It should be a preview of the Brilacidin pre print which is coming soon.The Brilacidin human cell study will be longer since more studies were performed and it will be more focused on Brilacidin as the only drug studied. It will include the SI number calculations. Hopefully it will include a number of direct comparisons with Remdesivir. I was hoping we would see a direct comparison of Brilacidin's SI to Remdesivir's SI in the 8/24/2020 PR.
It is interesting they compared Maraviroc to Remdesivir.
"Remdesivir was also screened for antiviral activity and possible synergy with Maraviroc. Toxicity of Remdesivir alone was below 10% for the concentrations that were screened. Combining Remdesivir with Maraviroc did not substantially increase cytotoxicity, and cell viability remained above 90%. Remdesivir alone decreased viral titer by 91.1% (p<0.0001). When Mara-viroc was added to the treatment viral titers were decreased by 94% (p<0.0001)."
Maraviroc, like Leronlimab,an approved AIDS drug which is a CCR5 receptor drugs which blocks viral entry into T cells. Both should have anti-inflammatory abilities.
From this study Maraviroc seems to inhibit Covid 19 after entry into cells while Leronlimab does not have a diect antiviral effect.
Maraviroc is recruiting patients for a human Covid 19 trials.
News 
Market Data 
Discover 
